Dutch drug company Lanthio Pharma has granted US-based Tarix Pharmaceuticals an exclusive license to its lanthionine-stabilized Angiotensin-(1-7) agonistic peptide for the treatment of acute lung injury.
Tarix will issue milestone payments and royalties to Lanthio in return for the license. Tarix will also finance further product development.
Lanthio Pharma CEO Bart Wuurman commented, "This deal with Tarix presents an early revenue opportunity and further validates the exciting potential of our technology to discover next generation peptide therapeutics that are more stable and more potent than classical peptides and hence have the characteristics that are required for successful innovative therapeutics."
The agonistic peptide was discovered by Lanthio Pharma, using its proprietary LanthioPep technology.
The compound is stable and resistant to angiotensin-converting enzymes, has high specificity for the MAS receptor, and shows increased intrinsic activity compared to wild-type Angiotensin-(1-7).
Caption: Lanthionine-stabilized Angiotensin-(1-7) is being developed for the treatment of acute lung injury and related indications with high unmet medical need. Credit: renjith krishnan
Twitter